Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Choosing Wisely in hemato-medical oncology

Choosing Wisely Cambodia 2023

Published: 28 Mar 2023

Views: 355

Rating:

Save

Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya

Dr Omar Abdihamid speaks to ecancer about his talk on the ‘Choosing Wisely in hemato-medical oncology’ at the "Choosing Wisely Cambodia 2023” congress, held in Phnom Penh on the 18th March 2023.

He highlights the key points from his talk covering diagnostics, the right to test, and value-based vs cost-based treatments.

Related Videos

The Vanessa Moss Prize: celebrating research into cancer health disparities

Dr Olubukola Ayodele - University Hospitals of Leicester NHS Trust, Leicester, UK

The Vanessa Moss Prize: celebrating research into cancer health disparities ( Dr Olubukola Ayodele - University Hospitals of Leicester NHS Trust, Leicester, UK )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Introducing oncology to undergraduate medical and allied health sciences students

Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India

Introducing oncology to undergraduate medical and allied health sciences students ( Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

Latest in immunological technologies that can treat, control, and prevent cancer

Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute

Latest in immunological technologies that can treat, control, and prevent cancer ( Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer